DelveInsight’s “Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Lymphocytic Leukemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chronic Lymphocytic Leukemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Lymphocytic Leukemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Lymphocytic Leukemia: An Overview
Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL) is an indolent malignancy characterized by increased production of mature but dysfunctional B lymphocytes. CLL and SLL are identical from a pathologic and immunophenotypic standpoint. Both CLL and SLL originate from B-cell lymphocytes, but present with different manifestations depending on where the abnormal cells are found. Usually, the initial leukemic phase represents CLL, where the cells are present in the blood. This eventually progresses to the lymphoma phase, representing SLL, where the cells are found in the lymph nodes.
CLL/SLL is defined as a monoclonal lymphoproliferative disease characterized by the proliferation and accumulation of morphologically mature but immunologically dysfunctional B-cell lymphocytes The primary disease sites include peripheral blood, spleen, lymph nodes, and bone marrow.
The exact etiology of Chronic Lymphocytic Leukemia is unknown. Genetic factors, rather than environmental factors, are the most likely cause of Chronic Lymphocytic Leukemia. However, a few known risk factors for Chronic Lymphocytic Leukemia include occupational causes by exposure to certain chemicals, radiation exposure, and tobacco users.
Chronic Lymphocytic Leukemia Market Key Facts
-
According to Surveillance, Epidemiology, and End Results (SEER), the rate of new cases of chronic lymphocytic leukemia was 4.7 per 100,000 men and women per year. These rates are age-adjusted and based on 2015-2019 cases and 2016-2020 deaths.
-
According to Kajuter et al. 2021, The age-standardized incidence rate is four to five cases per 100,000 person-years, and about 5500 patients in Germany are newly diagnosed with Chronic Lymphocytic Leukemia annually. Men are more often affected than women.
-
According to Cancer Research UK, Over the last decade, chronic lymphocytic leukemia incidence rates have increased by around a tenth (9%) in the UK. Rates in females have remained stable, and rates in males have increased by more than a twentieth (7%) (2015-2017).
-
According to Quinquenel et al. 2020, in 2018, the estimated number of new incident cases of Chronic Lymphocytic Leukemia in France was 4674. The male predominance is marked, with 59.3% of Chronic Lymphocytic Leukemia cases identified in men (2770 patients) and 40.7% of cases identified in women (1904 patients).4 The median age at diagnosis is 71 years in men and 73 years in women.
-
On January 19, 2023, the U.S. Food and Drug Administration (FDA) granted approval to BeiGene’s Brukinsa (Zanubrutinib), a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Chronic Lymphocytic Leukemia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Lymphocytic Leukemia pipeline therapies. It also thoroughly assesses the Chronic Lymphocytic Leukemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Chronic Lymphocytic Leukemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chronic Lymphocytic Leukemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chronic Lymphocytic Leukemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Lymphocytic Leukemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chronic Lymphocytic Leukemia Epidemiology, Segmented as –
-
Total Incidence of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)
-
Age-specific Incidence of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)
-
Treatable Cases of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)
-
Gender-specific Incidence of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)
-
Relapsed and Refractory Cases of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)
Chronic Lymphocytic Leukemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Lymphocytic Leukemia market or expected to be launched during the study period. The analysis covers the Chronic Lymphocytic Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Lymphocytic Leukemia drugs based on their sale and market share.
The report also covers the Chronic Lymphocytic Leukemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Lymphocytic Leukemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chronic Lymphocytic Leukemia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market
Chronic Lymphocytic Leukemia Therapeutics Analysis
The available treatment options for Chronic Lymphocytic Leukemia (CLL) vary depending on the patient’s age, disease risk group, and the displayed symptoms. The goal of treatment for the patient is the induction of remission and prolonging life while minimizing treatment-related adverse effects. There is an exception for allogeneic hematopoietic stem cell transplantation (HSCT), none of the current therapies are considered curative, but a subset of patients experiences long-term remissions.
Looking at the treatment options CLL has seen a significant evolution in the past decades. The historical standard of initial chemotherapy with chlorambucil has been largely replaced with more effective chemoimmunotherapy regimens incorporating monoclonal antibodies (mAbs) targeting CD20 (rituximab [Rituxan], obinutuzumab [Gazyva], and ofatumumab [Arzerra]), and targeted therapy with the small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), ibrutinib (Imbruvica).
Several major pharma and biotech companies are developing therapies for chronic lymphocytic leukemia. Currently, Loxo Oncology is leading the therapeutics market with its chronic lymphocytic leukemia drug candidates in the most advanced stage of clinical development.
Chronic Lymphocytic Leukemia Companies Actively Working in the Therapeutics Market Include
AFA Insurance, Astex Pharmaceuticals, BeiGene, Bristol Myers Squibb, Celgene, Cellectar Biosciences, Inc., Gilead Sciences, Incyte Corporation, IO Biotech, Janssen Research & Development, LLC, Loxo Oncology, MorphoSys AG, Novartis, Octapharma, Oncternal Therapeutics, TG Therapeutics, TG therapeutics, Zhejiang DTRM Biopharma, and many others.
Emerging and Marketed Chronic Lymphocytic Leukemia Therapies Covered in the Report Include:
-
Olaptesed pegol: NOXXON Pharma
-
Zanubrutinib: BeiGene
-
KTE-X19: Kite, a Gilead Company
-
Ublituximab: TG Therapeutics
-
LOXO305: Loxo Oncology
-
Cirmtuzumab: Oncternal Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Lymphocytic Leukemia Competitive Intelligence Analysis
4. Chronic Lymphocytic Leukemia Market Overview at a Glance
5. Chronic Lymphocytic Leukemia Disease Background and Overview
6. Chronic Lymphocytic Leukemia Patient Journey
7. Chronic Lymphocytic Leukemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chronic Lymphocytic Leukemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Lymphocytic Leukemia Unmet Needs
10. Key Endpoints of Chronic Lymphocytic Leukemia Treatment
11. Chronic Lymphocytic Leukemia Marketed Therapies
12. Chronic Lymphocytic Leukemia Emerging Drugs and Latest Therapeutic Advances
13. Chronic Lymphocytic Leukemia Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Lymphocytic Leukemia Market Outlook (In US, EU5, and Japan)
16. Chronic Lymphocytic Leukemia Companies Active in the Market
17. Chronic Lymphocytic Leukemia Access and Reimbursement Overview
18. KOL Views on the Chronic Lymphocytic Leukemia Market
19. Chronic Lymphocytic Leukemia Market Drivers
20. Chronic Lymphocytic Leukemia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Febrile Neutropenia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Febrile Neutropenia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research